Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
Inavo121
Breast Cancer Phase III
- 13.4 weeks
- 1st site activated in Canada
Inavo121
Breast Cancer Phase III
- 19.2 weeks
- 2nd site activated in Canada
Inavo121
Breast Cancer Phase III
- 19 weeks
- 3rd site activated in Canada
Inavo122
Breast Cancer Phase III
- 16.4 weeks
- 1st site activated in Canada
Inavo122
Breast Cancer Phase III
- 9 weeks
- 2nd site activated in Canada
KRAS
Lung Cancer Phase III
- 11.6 weeks
- 1st site activated in Canada
KRAS
Lung Cancer Phase III
- 8.6 weeks
- 2nd site activated in Canada
KRAS
Lung Cancer Phase III
- 7.2 weeks
- 3rd site activated in Canada
VICTORION-1
Cardiology Phase III
- 12.8 weeks
- 1st public site activated in Canada
VICTORION-1
Cardiology Phase III
- 6.2 weeks
EFC15951
Myeloma Phase III
- 19.1 weeks
- Canadian regulatory delay 1st site activated in Canada
EFC15951
Myeloma Phase III
- 21.9 weeks
- Canadian regulatory delay 2nd site activated in Canada
MASTER-1
Rare Disease Phase II
- 8 weeks
- 1st site activated in Canada
NEOS
Adolescents MS Phase III
- 7 weeks
- 1st site activated in Canada
NEOS
Adolescents MS Phase III
- 6.1 weeks
NEPTUNUS-2
Auto-immune Diseases Phase III
- 8.6 weeks
- 1st site activated in Canada and Canadian FPI
NEPTUNUS-2
Auto-immune Diseases Phase III
- 14.3 weeks
- 2nd site activated in Canada
ONWARDS
Arthritis Phase II
- 9.1 weeks
- Ongoing study
PKM16982
Urticaria Phase III
- 8.4 weeks
- 2nd site activated in Canada
STRENGTH
Spinal Muscular Atrophy Phase II
- 12.1 weeks
- 1st site activated in Canada